Suresh S. Ramalingam, MD, FASCO, discusses the potential of HER2 as a driver mutation in non–small cell lung cancer.
Suresh Ramalingam, MD, FASCO, Winship Cancer Institute of Emory University
Advertisement
Articles by Suresh Ramalingam, MD, FASCO, Winship Cancer Institute of Emory University
Advertisement
Latest Updated Articles
Dr. Ramalingam on the Potential of HER2 as a Driver Mutation in NSCLCPublished: January 14th 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5